Niagen Bioscience, Inc. (NAGE)

In the past six months, Niagen Bioscience Inc. experienced several events impacting its stock price. In October 2025, the company raised its full-year revenue guidance, projecting 25-30% year-over-year growth. In December 2025/January 2026, Niagen Bioscience acquired a comprehensive patent portfolio covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast. Niagen Bioscience was scheduled to report its Third Quarter 2025 financial results on November 4, 2025. In January 2026, the stock has shown some volatility. The company announced a $10 million share repurchase program.

The provided search results do not contain specific information regarding the demand seasonality for Niagen Bioscience, Inc. products and services.

Niagen Bioscience, Inc. (NAGE), formerly ChromaDex Corporation, is a global bioscience company founded in 1999 and headquartered in Los Angeles, California. Operating in the healthcare sector, focusing on biotechnology and dietary supplements, the company centers on healthy aging and NAD+ science, advancing healthspan through precision science and innovative NAD+-boosting solutions. Its core business involves developing and commercializing its patented nicotinamide riboside (NR) ingredient, Niagen®, clinically proven to increase NAD+ levels, a coenzyme vital for mitochondrial bioenergetics, metabolic homeostasis, and genomic stability. The company's major products and services include Tru Niagen®, Niagen® Plus, Niagen® (Ingredient Technology), analytical reference standards and services, NAD+ test kits, and Tru Niagen® Beauty.

Niagen Bioscience Inc. is a global bioscience company headquartered in Los Angeles, California, United States. Its Tru Niagen products are distributed to consumers and distributors globally, and it has research collaborations with global research institutions.

Niagen Bioscience has a reputation as a leader in NAD+ science and healthy-aging research, distinguished by uncompromising scientific standards over 25 years. The company changed its name from ChromaDex to Niagen Bioscience, Inc. in March 2025. The acquisition of a comprehensive patent portfolio for nicotinamide riboside from Queen's University Belfast further reinforced its leadership in NAD+ precursor technologies. The launch of Tru Niagen® Beauty, the first NAD+ skincare supplement in the U.S., demonstrates continued innovation. Ongoing investment in research on nicotinamide riboside and its role in increasing NAD+ levels, in partnership with multiple research institutions, contributes to its scientific credibility. The company announced results from the first-ever randomized controlled trial exploring Niagen® supplementation in Long COVID.

The provided search results do not contain specific details about major institutional and individual owners of Niagen Bioscience, Inc.